BerGenBio and Oncoinvent Proposed Merger Overview
In a significant development within the biotechnology sector, BerGenBio ASA and Oncoinvent ASA have announced their plans for a merger. The merger aims to combine both companies into a single entity with BerGenBio as the acquiring company, fostering a collaborative approach to advancing innovative cancer therapies.
Details of the Merger and Financial Implications
Following the proposed merger, BerGenBio intends to conduct a fully underwritten rights issue. This move is designed to ensure that the combined company leverages its financial resources for strategic growth and development. The exchange ratio has been set, giving BerGenBio shareholders 25% of the newly merged entity while Oncoinvent shareholders will hold 75%. This arrangement will translate to a strong collaborative effort to advance the clinical strategies for treating cancer.
The financial aspects of the merger reveal a valuation of BerGenBio at NOK 65 million, offering a substantial premium compared to potential distributions in a liquidation situation. Meanwhile, Oncoinvent's valuation stands at NOK 195.5 million, indicating robust potential for future growth.
Funding and Shareholder Benefits
Importantly, the merger is expected to introduce approximately NOK 45 million in cash, to support Oncoinvent’s clinical development initiatives. This cash influx will significantly bolster the company’s capacity to innovate and deliver effective cancer treatments. Additionally, the merger will enhance the shareholder base, thereby improving liquidity and preparing for a potential uplisting on the stock exchange.
Support from Major Shareholders
The merger is backed by pivotal shareholders from both companies. Notable names such as Meteva AS and Hadean Capital I AS have publicly supported the merger, committing to lock-up agreements to enhance stability in this transformational phase.
Management Insights and Future Prospects
Leadership from both companies expressed positive sentiments about the merger. Anders Tullgren, chair of BerGenBio, highlighted the strategic review underlying this decision. The merger combines both firms' strengths, showcasing a commitment to utilizing Norwegian radiopharmaceutical technology that has yielded promising clinical outcomes. The combined efforts are poised to provide shareholders with promising opportunities in the biotechnological landscape.
Øystein Soug, the CEO of Oncoinvent, echoed this enthusiasm, emphasizing their strong strategic position moving forward with the phase 2 trial of Radspherin in treating ovarian cancer. He believes this merger positions the company as a transformative entity within the radiopharmaceutical sector dedicated to enhancing patient outcomes.
About Oncoinvent
Oncoinvent is a clinical-stage biotechnology firm specializing in innovative radiopharmaceuticals targeted at cancer treatment. Its lead candidate, Radspherin, is noted for its targeted approach to treating micro-metastases following surgery, effectively utilizing modern medical technologies to improve patient life expectancy without the complex challenges of other therapies. Areas of ongoing investigation include colorectal cancer and ovarian cancer, bolstered by encouraging clinical efficacy data.
Operational and Production Capabilities
The Oncoinvent team operates a state-of-the-art facility in Oslo for the advanced production of clinical trial products. With a heritage ensured by founders who played pivotal roles in Norway’s successful cancer treatment advancements, Oncoinvent is well-equipped to lead transformative changes in patient care.
Next Steps and Shareholder Engagement
Once legally validated, the merged entity will be managed by a new Board with representatives from both BerGenBio and Oncoinvent. Current management from BerGenBio will transition out following the merger completion, allowing Oncoinvent's leadership to steer the newly formed company. Shareholders from both companies will have the opportunity to participate in the rights issue upon the merger's finalization, ensuring equitable treatment across the board.
It is anticipated that all necessary approvals for the merger would be finalized by September, laying the groundwork for a productive transition period that will support the ongoing trials and company growth.
Frequently Asked Questions
What is the significance of the merger between BerGenBio and Oncoinvent?
The merger aims to combine strengths and enhance the development of innovative cancer therapies, potentially providing better treatment outcomes for patients.
How will shareholders be affected by the merger?
Shareholders are expected to benefit from increased liquidity and a stronger combined capital base, which will enhance their investment value in the merged company.
What is Radspherin and its relevance in cancer treatment?
Radspherin is a cutting-edge radiopharmaceutical intended for targeting micro-metastases. Its development is a key focus in the merger, aimed at providing significant clinical benefits.
When is the expected timeline for the merger completion?
The merger is projected to be finalized around mid-September, pending necessary approvals from both companies' extraordinary general meetings.
Will there be any changes in the management structure post-merger?
Yes, following the merger, Oncoinvent’s current management will lead the newly formed company, while BerGenBio's management will step down.
